Al18F-PSMA-BCH PET/CT

Phase 2Small molecule

CCancer Institute and Hospital, Chinese Academy of Medical Sciences

Al18F-PSMA-BCH PET/CT is one of 4 small molecule programs targeting Prostate. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ProstateRecruiting

ProstatePhase 2

Recruiting

Competition

Competitive Landscape

3 competitors in Prostate

#DrugCompanyPhaseTrials

Tamsulosin OCAS

Astellas

Phase 3

1 2

Erleada

Johnson & Johnson

Phase 1

1 3

Avodart

Akero Therapeutics

Preclinical

4 4

Al18F-PSMA-BCH PET/CT

CCancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Prostate1 trial

Application of 18F-PSMA PET / CT Imaging in Prostate Specific Membrane Antigen Positive Tumor

Recruiting·—·Phase 2·NCT05761366·400 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Al18F-PSMA-BCH PET/CT. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Al18F-PSMA-BCH PET/CT compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Al18F-PSMA-BCH PET/CT. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Cancer Institute and Hospital, Chinese Academy of Medical Sciences company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: CCancer Institute and Hospital, Chinese Academy of Medical Sciences

Al18F-PSMA-BCH PET/CT

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Prostate1 trial

References

Drug Info

Quick Facts

Related News